CMND
Clearmind Medicine·NASDAQ
--
--(--)
--
--(--)
CMND fundamentals
During Q1 2026, Clearmind Medicine (CMND) reported revenue of --, a YoY change of 0.00%. Net income was -3.85M, a YoY change of -259.70%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | Q1,2026 | TTM |
|---|
Start Date | Feb 1, 2021 | May 1, 2021 | Aug 1, 2021 | Nov 1, 2021 | Feb 1, 2022 | May 1, 2022 | Aug 1, 2022 | Nov 1, 2022 | Feb 1, 2023 | May 1, 2023 | Aug 1, 2023 | Nov 1, 2023 | Feb 1, 2024 | May 1, 2024 | Aug 1, 2024 | Nov 1, 2024 | Feb 1, 2025 | May 1, 2025 | Aug 1, 2025 | Nov 1, 2025 | -- |
End Date | Apr 30, 2021 | Jul 31, 2021 | Oct 31, 2021 | Jan 31, 2022 | Apr 30, 2022 | Jul 31, 2022 | Oct 31, 2022 | Jan 31, 2023 | Apr 30, 2023 | Jul 31, 2023 | Oct 31, 2023 | Jan 31, 2024 | Apr 30, 2024 | Jul 31, 2024 | Oct 31, 2024 | Jan 31, 2025 | Apr 30, 2025 | Jul 31, 2025 | Oct 31, 2025 | Jan 31, 2026 | -- |
Fiscal Year-End | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | Oct 31 | -- |
Revenue | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Cost of Revenue | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | 153.62K -- | 868.53K -- | -- -- | 1.64M -- | 2.22M +1345.50% | 1.35M +55.54% | 1.15M -- | 1.83M +11.63% | 1.66M -25.43% | 1.10M -18.36% | 1.71M +48.47% | 1.38M -24.50% | 1.30M -21.29% | 1.47M +33.40% | 1.59M -7.32% | 1.50M +8.11% | 1.31M +0.27% | 1.41M -4.31% | 1.46M -8.19% | 3.66M +144.62% | 7.83M -- |
Selling, General and Administrative Expenses | 153.62K -- | 822.59K -- | -- -- | 1.31M -- | 1.06M +589.92% | 1.03M +24.67% | -131.31K -- | 1.25M -4.77% | 1.34M +26.28% | 838.92K -18.20% | 1.34M +1117.71% | 1.16M -7.14% | 980.55K -26.74% | 1.13M +34.14% | 1.10M -17.71% | 1.03M -10.53% | 855.12K -12.79% | 684.72K -39.16% | 1.04M -5.78% | 3.02M +191.81% | 5.60M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 3.17M -- | -- -- | -- -- | 838.92K -- | 1.34M -57.85% | 1.16M -- | 980.55K -- | 1.13M +34.14% | 1.10M -17.71% | 1.03M -10.53% | 855.12K -12.79% | 684.72K -39.16% | 1.04M -5.78% | 3.02M +191.81% | 5.60M -- |
Research and Development Expenses | -- -- | 45.93K -- | -- -- | 334.22K -- | 1.16M -- | 325.32K +608.25% | 1.28M -- | 587.63K +75.82% | 317.57K -72.64% | 263.95K -18.86% | 375.07K -70.79% | 227.48K -61.29% | 322.96K +1.70% | 345.88K +31.04% | 486.49K +29.71% | 461.44K +102.85% | 451.86K +39.91% | 723.05K +109.04% | 420.18K -13.63% | 640.49K +38.80% | 2.24M -- |
Operating Income | -153.62K -- | -868.53K -- | -- -- | -1.64M -- | -2.22M -1345.50% | -1.35M -55.54% | -1.15M -- | -1.83M -11.63% | -1.66M +25.43% | -1.10M +18.36% | -1.71M -48.47% | -1.38M +24.50% | -1.30M +21.29% | -1.47M -33.40% | -1.59M +7.32% | -1.50M -8.11% | -1.31M -0.27% | -1.41M +4.31% | -1.46M +8.19% | -3.66M -144.62% | -7.83M -- |
Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -5.09K -- | -105.15K -- | -132.14K -- | -382.69K -- | -63.03K -1137.74% | -411.10K -290.98% | 521.06K +494.33% | -2.35M -513.29% | 217.69K +445.39% | 432.04K +205.10% | -580.08K -211.33% | 798.56K +134.03% | 463.89K +113.09% | 543.71K +25.85% | 102.43K +117.66% | 770.61K -3.50% | -190.71K -141.11% | 1.23M -- |
Gain (Loss) on Other Investment | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | 0 -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -598.76K -- | -- -- | -- -- | 470.11K -- | -2.35M -292.22% | 155.70K -- | 396.83K -- | -643.23K -236.82% | 729.87K +131.08% | 443.05K +184.55% | 507.69K +27.93% | 75.96K +111.81% | 737.20K +1.00% | -257.51K -158.12% | 1.06M -- |
Gain (Loss) on Foreign Currency Exchange | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -404 -- | -- -- | -- -- | 33.65K -- | -16.43K -3965.59% | 1.42K -- | 1.25K -- | -5.38K -115.99% | -3.32K +79.79% | -4.45K -414.27% | 2.25K +78.96% | 3.07K +157.03% | 2.51K +175.75% | 6.26K +240.72% | 14.09K -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -5.09K -- | -105.15K -- | -121.01K -- | 216.47K -- | -81.04K -1491.52% | -417.06K -296.65% | 17.31K +114.30% | -41.29K -119.07% | -2.93K +96.39% | 33.95K +108.14% | -77.91K -550.14% | 46.88K +213.54% | -8.71K -197.85% | -7.87K -123.17% | -9.19K +88.20% | 25.77K -45.02% | -4.11K +52.87% | 4.61K -- |
Net Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | 11.13K -- | 0 -- | -18.02K -- | -5.97K -- | -- -- | -59.17K -- | -63.50K -252.50% | 0 +100.00% | -146.43K -- | -25.13K +57.53% | -34.01K +46.45% | -41.65K -- | -32.59K +77.74% | -5.12K +79.62% | -64.65K -90.10% | -144.01K -- |
Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 10.89K -- | -- -- | -- -- | -- -- | 36.16K +231.94% | -- -- | -- -- | -- -- | 19.54K -45.97% | -- -- | -- -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 18.02K -- | 5.97K -- | -- -- | 70.07K -- | 63.50K +252.50% | 0 -100.00% | 146.43K -- | 61.29K -12.53% | 34.01K -46.45% | 41.65K -- | 32.59K -77.74% | 24.66K -59.77% | 64.65K +90.10% | 163.55K -- |
Pretax Income From Continuing Operations | -153.62K -- | -868.53K -- | -1.90M -- | -1.65M -- | -2.33M -1413.95% | -1.48M -70.75% | -1.54M +18.99% | -1.90M -15.11% | -2.07M +11.12% | -581.82K +60.77% | -4.06M -164.32% | -1.17M +38.49% | -871.46K +57.84% | -2.05M -252.57% | -787.62K +80.59% | -1.03M +11.49% | -763.27K +12.41% | -1.31M +36.37% | -685.65K +12.95% | -3.85M -273.02% | -6.60M -- |
Income Tax Expense | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 29.86K -- | 3.38K -- | 9.27K -- | -6.63K -- | 11.35K -61.98% | 201.50K +5856.25% | 36.76K +296.63% | 42.59K +742.29% | 97.12K +755.46% | 39.34K -80.48% | 20.66K -43.80% | 8.26K -80.61% | 2.19K -97.74% | 3.96K -89.93% | 35.07K -- |
Net Income | -153.62K -- | -868.53K -- | -1.90M -- | -1.65M -- | -2.33M -1413.95% | -1.48M -70.75% | -1.57M +17.41% | -1.90M -15.32% | -2.08M +10.72% | -575.19K +61.21% | -4.07M -160.00% | -1.37M +27.99% | -908.22K +56.26% | -2.09M -264.04% | -884.74K +78.26% | -1.07M +21.65% | -783.93K +13.68% | -1.31M +37.27% | -687.84K +22.26% | -3.85M -259.70% | -6.64M -- |
Net Income Attributable to Owners of the Company | -153.62K -- | -868.53K -- | -- -- | -1.65M -- | -2.33M -1413.95% | -1.48M -70.75% | -1.57M -- | -1.90M -15.32% | -2.08M +10.72% | -575.19K +61.21% | -4.07M -160.00% | -1.37M +27.99% | -908.22K +56.26% | -2.09M -264.04% | -884.74K +78.26% | -1.07M +21.65% | -783.93K +13.68% | -1.31M +37.27% | -687.84K +22.26% | -3.85M -259.70% | -6.64M -- |
Net Income Attributable to Common Stockholders | -153.62K -- | -868.53K -- | -- -- | -1.65M -- | -2.33M -1413.95% | -1.48M -70.75% | -1.57M -- | -1.90M -15.32% | -2.08M +10.72% | -575.19K +61.21% | -4.07M -160.00% | -1.37M +27.99% | -908.22K +56.26% | -2.09M -264.04% | -884.74K +78.26% | -1.07M +21.65% | -783.93K +13.68% | -1.31M +37.27% | -687.84K +22.26% | -3.85M -259.70% | -6.64M -- |
Other Comprehensive Income | -- -- | -12.13K -- | 12.20K -- | -- -- | -- -- | -- -- | -21.25K -274.21% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Total Comprehensive Income | -153.62K -- | -880.66K -- | -1.88M -- | -1.65M -- | -2.33M -1413.95% | -1.48M -68.40% | -1.59M +15.75% | -1.90M -15.32% | -2.08M +10.72% | -575.19K +61.21% | 4.55M +386.85% | -1.37M +27.99% | -908.22K +56.26% | -2.09M -264.04% | 4.37M -3.98% | -1.07M +21.65% | -783.93K +13.68% | -1.31M +37.27% | 3.17M -27.48% | -3.85M -259.70% | -2.78M -- |
Total Comprehensive Income Attributable to Owners of the Company | -153.62K -- | -880.66K -- | -- -- | -1.65M -- | -2.33M -1413.95% | -1.48M -68.40% | -1.59M -- | -1.90M -15.32% | -2.08M +10.72% | -575.19K +61.21% | 4.55M +386.85% | -1.37M +27.99% | -908.22K +56.26% | -2.09M -264.04% | 4.37M -3.98% | -1.07M +21.65% | -783.93K +13.68% | -1.31M +37.27% | 3.17M -27.48% | -3.85M -259.70% | -2.78M -- |
Basic EPS | -0.01 -- | -0.81 -- | -- -- | -1.32 -- | -1.78 -17700.00% | -1.12 -38.27% | -- -- | -24.8 -1778.79% | -16.62 -833.71% | -2.43 -116.96% | -0.28 -- | -0.9 +96.37% | -0.28 +98.32% | -0.59 +75.72% | -0.21 +25.00% | -9.55 -961.11% | -0.16 +42.86% | -0.25 +57.63% | -0.13 +38.10% | -3.32 +65.24% | -3.86 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -2.43 -- | -- -- | -0.9 -- | -0.28 -- | -0.59 +75.72% | -- -- | -9.55 -961.11% | -0.16 +42.86% | -0.25 +57.63% | -- -- | -3.32 +65.24% | -- -- |
Diluted EPS | -0.01 -- | -0.81 -- | -- -- | -1.32 -- | -1.78 -17700.00% | -1.12 -38.27% | -- -- | -24.8 -1778.79% | -16.62 -833.71% | -2.43 -116.96% | -- -- | -0.9 +96.37% | -0.28 +98.32% | -0.59 +75.72% | -- -- | -9.55 -961.11% | -0.16 +42.86% | -0.25 +57.63% | -- -- | -3.32 +65.24% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -2.43 -- | -- -- | -0.9 -- | -0.28 -- | -0.59 +75.72% | -- -- | -9.55 -961.11% | -0.16 +42.86% | -0.25 +57.63% | -- -- | -3.32 +65.24% | -- -- |
You can ask Aime
What factors drove the changes in Clearmind Medicine's revenue and profit?Did Clearmind Medicine beat or miss consensus estimates last quarter?What were the key takeaways from Clearmind Medicine’s earnings call?What guidance did Clearmind Medicine's management provide for the next earnings period?What is the revenue and EPS growth rate for Clearmind Medicine year over year?What is Clearmind Medicine's latest dividend and current dividend yield?What is the market's earnings forecast for Clearmind Medicine next quarter?What is Clearmind Medicine's gross profit margin?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
